Nasdaq: AERI

Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop that has demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in clinical trials. In addition, AERI is developing Roclatan, a once-daily quadruple-action single drop combination of Rhopressa plus latanoprost, that has also demonstrated the ability to reduce IOP in clinical trials.

We believe that Aerie’s products have the potential to play a significant role in the treatment of glaucoma. Aerie typifies the companies Foresite Capital looks for, with multiple late-stage products in a large yet underserved market, and a strong and proven management team.